Clinical Trial Update: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CFT1946 as monotherapy and in combination for BRAF V600-mutant solid tumors to assess safety, tolerability, and preliminary efficacy. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma
• Colorectal Cancer
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• CFT1946

Snippet

Sponsor: C4 Therapeutics, Inc. | Conditions: Solid Tumors, Melanoma | Phase 1 | Status: COMPLETED